In trials and real-world experience, people have used GLP-1 medications safely for many years
About Our Factory & Business Background Business Type Trading Company Address Shijiazhuang, Hebei, China Plant Area 50 square meters Number of Employees 5 Registered Capital 10,000 RMB Terms of Payment T/T, PayPal, LC, Western Union International Commercial Terms(Incoterms) FOB, CIF, CFR, EXW Average Lead Time Peak Season Lead Time: within 15 workdays Off Season Lead Time: within 15 workdays Nearest Port Tianjin Port Minimum Order Quantity 1 Supply Chain Partners 5 Our Production Capability & Technical Expertise Main Products Hyaluronic Acid Customization Options Customization from Samples, Customization from Designs, Full Customization, Minor Customization, Flexible customization OEM Service Available Yes R&D Engineers 1 people Our Industry Experience & Global Business Record Year of Establishment 2024-07-05 Export Year 1 Year Main Markets North America, South America, Europe, East Asia(Japan/ South Korea), Australia Repeat Buyers Choice 30%~50% Number of Foreign Trading Staff 4 Overseas Agent/Branch No New Products Launched in Last year No Our Certifications, Standards & Industry Recognition Cooperated with Fortune 500 No FAQ What is the dosage for different age groups
Tirzepatide: Safety Considerations for Different Profiles Semaglutide acts solely on GLP-1 receptors and shows excellent long-term safety data from cardiovascular outcome trials
BMI and Body Weight: GLP-1 RAs were associated with notable reductions in both body mass index (BMI) and body weight across a wide range of populations
